Market Chatter: 'Business as Usual' for China Drugmakers Despite Scrutiny of Cross-Border Tech Deals, JW Therapeutics CEO Says
The Chinese pharmaceutical sector remains unaffected by Beijing's restrictions on cross-border deals involving sensitive technology, Reuters reported Tuesday, citing JW (Cayman) Therapeutics (HKG:2126) CEO Leo Tian."For us, everything is business as usual. Our cross-border collaborations, especially in CGT (cell and gene therapies), are particularly dependent on international cooperation," Reuters quoted Tian as saying.JW is "actively seeking cooperation" with companies outside China for assets in its pipeline, the report said, citing Tian.Global pharmaceutical companies have been ramping up their search for China‑developed experimental drugs in a bid to cut costs before their patents expire, Reuters said.Industry analysts have forecast drug licensing deals to rise to a record in 2026, the report said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
